These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12096606)

  • 1. Sam's club.
    Kadlec D
    Time; 2002 Jun; 159(25):48-50. PubMed ID: 12096606
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Sam's Club a game-changer?
    Anderson H; Goedert J
    Health Data Manag; 2009 May; 17(5):10. PubMed ID: 19492591
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology becomes the new dot com.
    Dorey E
    Nat Biotechnol; 2000 Feb; 18(2):140. PubMed ID: 10657108
    [No Abstract]   [Full Text] [Related]  

  • 4. Balance is returning after US biotechnology shares scare.
    Wadman M
    Nature; 2000 Mar; 404(6777):424. PubMed ID: 10761882
    [No Abstract]   [Full Text] [Related]  

  • 5. Placing a bet on biotech.
    Greenberg H
    Fortune; 2002 Dec; 146(13):188. PubMed ID: 12510567
    [No Abstract]   [Full Text] [Related]  

  • 6. IPOs: is the party really over?
    Nat Biotechnol; 1999 May; 17(5):405. PubMed ID: 10331776
    [No Abstract]   [Full Text] [Related]  

  • 7. Partnering up in Q3.
    Lawrence S
    Nat Biotechnol; 2007 Nov; 25(11):1200. PubMed ID: 17989659
    [No Abstract]   [Full Text] [Related]  

  • 8. Investment analysts paint rosy prospect for biotech.
    Lehrman S
    Nature; 1997 Jan; 385(6613):189. PubMed ID: 9000060
    [No Abstract]   [Full Text] [Related]  

  • 9. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 10. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomics stocks: profiting from biotech.
    Sherrid P
    US News World Rep; 2000 Jan; 128(4):57. PubMed ID: 11184126
    [No Abstract]   [Full Text] [Related]  

  • 12. The rise of venture capital and biotechnology in the US and Europe.
    Lee DP; Dibner MD
    Nat Biotechnol; 2005 Jun; 23(6):672-6. PubMed ID: 15940233
    [No Abstract]   [Full Text] [Related]  

  • 13. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 14. Delisting threat looms large on biotech front.
    Lawrence S
    Nat Biotechnol; 2005 Jan; 23(1):5. PubMed ID: 15637598
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomics companies boom on New York stock exchange.
    Smaglik P
    Nature; 2000 Jan; 403(6765):4. PubMed ID: 10651566
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 17. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnology. Stem cells lose market luster.
    Vogel G
    Science; 2003 Mar; 299(5614):1830-1. PubMed ID: 12649456
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 20. When a long shot is worth a shot.
    Jacobs T; Fischer J
    Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.